Rhythm Pharmaceuticals reports Q4 EPS (70c), consensus (70c)

Reports Q4 revenue $24.2M, consensus $25.38M. “2023 was a strong year for us as we delivered IMCIVREE and provided support for patients and families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway diseases in 14 countries, including the United States,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “We began this year by meaningfully strengthening our pipeline with RM-718 ready to enter the clinic and with the acquisition of the global rights to LB54640. Importantly, we remain focused on developing setmelanotide to treat patients with hypothalamic obesity, for whom there are no approved therapies. We are pleased to have completed enrollment in our global Phase 3 trial in hypothalamic obesity and to have achieved alignment with Japanese authorities on an efficient path to develop setmelanotide for patients with hypothalamic obesity.”